Table 6.
Patient-level outcomes: incremental costs associated with poor glycemic control and failure to intensify therapy (baseline HbA1c of 11.0% [97 mmol/mol], target HbA1c of 7.0% [53 mmol/mol])
| Intensification delay, years | Time horizon, years | |||||
|---|---|---|---|---|---|---|
| 1 | 2 | 3 | 5 | 10 | 30 | |
| Reduction in life expectancy with poor glycemic control, years | ||||||
| 1 | 0.005 | 0.01 | 0.01 | 0.01 | 0.04 | 0.13 |
| 2 | – | 0.01 | 0.01 | 0.02 | 0.06 | 0.20 |
| 3 | – | – | 0.01 | 0.02 | 0.07 | 0.28 |
| 5 | – | – | – | 0.03 | 0.10 | 0.42 |
| 7 | – | – | – | – | 0.12 | 0.59 |
| Cost of diabetes-related complications, USD | ||||||
| 1 | 327 | 550 | 715 | 1016 | 1744 | 3283 |
| 2 | – | 755 | 1098 | 1654 | 3033 | 5813 |
| 3 | – | – | 1297 | 2182 | 4111 | 8070 |
| 5 | – | – | – | 2721 | 5919 | 12,212 |
| 7 | – | – | – | – | 7191 | 15,663 |
| Lost productivity costs, USD | ||||||
| 1 | 1070 | 1671 | 2210 | 3192 | 5843 | 6624 |
| 2 | – | 2483 | 3438 | 5188 | 9557 | 11,039 |
| 3 | – | – | 4233 | 6736 | 12,606 | 14,763 |
| 5 | – | – | – | 8356 | 17,540 | 20,689 |
| 7 | – | – | – | – | 20,683 | 25,277 |
| Total costs, USD | ||||||
| 1 | 1396 | 2221 | 2925 | 4208 | 7588 | 9908 |
| 2 | – | 3239 | 4537 | 6843 | 12,589 | 16,851 |
| 3 | – | – | 5530 | 8917 | 16,717 | 22,833 |
| 5 | – | – | – | 11,077 | 23,460 | 32,901 |
| 7 | – | – | – | – | 27,873 | 40,940 |
HbA1c glycated hemoglobin, USD United States dollars